Arbutus Biopharma (ABUS) 10-Q2018 Q1 Quarterly report

Filed: 4 May 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AASLD, accompanied, accrual, Agency, al, alafenamide, ALNY, amalgamated, antisense, APOLLO, approach, ARIAD, ATTR, Authorization, BC, Bo, build, Burnaby, Chairman, Characterization, closure, Codification, commitment, compatible, component, connection, coupon, deciding, deeper, deferral, deficit, deliverable, depreciation, disoproxil, disposal, disproxil, dominant, Dr, dual, durable, EMA, employee, encapsidation, entecavir, estate, ETV, European, exit, experience, feasibility, feature, flexible, Food, fumarate, Genevant, Hansen, ideal, Identification, industry, interface, inventory, Konstantin, Kowdley, ligand, Linnik, lt, Lutwyche, mechanistically, mg, minimum, MOA, model, moderately, Moderna, Nasdaq, nucleic, Organization, organizational, owner, ownership, PA, PegIFN, people, permanent, Peter, pgRNA, predetermined, preservation, President, proceed, professional, prolonged, pursue, rapidly, ratably, rateably, ratio, rcDNA, readily, redemption, regularly, relocation, render, repaid, repayment, replacement, restructuring, retention, reversal, robust, Rode, satisfied, seed, Senior, site, Small, SOC, stockholder, striking, suitable, suppressed, suppression, survive, survived, TAF, TDF, team, technical, tiered, titled, transthyretin, TTR, undetectable, vaccine, viability, VP, wait, wholly, workforce, world

Removed: absence, accuracy, advancement, Agricultural, agriculture, analog, apply, applying, arrangement, begin, biology, clarify, classify, comparing, creating, departure, depend, depict, derived, determining, Dicerna, directed, discontinuance, discontinuation, discontinued, dosed, earliest, eliminating, expired, explain, explained, exploration, explore, frame, gain, Hyperoxaluria, identified, implied, impracticable, instrument, mathematical, mediate, Monsanto, month, occurred, PADCo, permitted, practicable, predominant, prescribed, preventing, principle, procedure, proportion, prospectively, reactivating, reconciling, record, reimbursable, remediate, request, retrospectively, revised, separated, Simplifying, smaller, specifically, step, Sterilizer, subsidiary, Subtopic, Supply, sustained, test, transition, underlying, unexercised, unit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABUS transcripts

ABUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.	The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

Date: May 3, 2018



	/s/ Mark Murray
	Name: Mark Murray
	Title: President and Chief Executive Officer